Ashley Bigaran1,2, Eva Zopf3, Jason Gardner4, Andre La Gerche5,6, Declan G Murphy7,8, Erin J Howden5, Michael K Baker9, Prue Cormie3,10,11. 1. Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia. ashley.bigaran@acu.edu.au. 2. Department of Sports Cardiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia. ashley.bigaran@acu.edu.au. 3. Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia. 4. School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Victoria, Australia. 5. Department of Sports Cardiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia. 6. Cardiology Department, St Vincent's Hospital, Melbourne, Victoria, Australia. 7. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 8. The Sir Peter MacCallum Department of Urology, University of Melbourne, Melbourne, Victoria, Australia. 9. School of Behavioural and Health Sciences, Australian Catholic University, Sydney, New South Wales, Australia. 10. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 11. The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Abstract
BACKGROUND: Growing evidence suggests that men exposed to androgen deprivation therapy (ADT) have an increased risk of cardiovascular disease. While exercise has shown to attenuate some adverse effects of ADT, the effects on cardiometabolic health have not been systematically evaluated. OBJECTIVE: To evaluate the effect of exercise on cardiometabolic health in men with prostate cancer (PCa) receiving ADT. METHODS: A systematic literature search of MEDLINE, EMBASE, CINHAL, SCOPUS, WEB OF SCIENCE and SPORTSDICUS from database inception to April 2020 was performed. A quantitative synthesis using Cohens d effect size and a meta-analysis using random-effects models were conducted. RESULTS: Overall, fourteen randomised controlled trials (RCTs) and four non-randomised studies were included. Eleven RCTs (n = 939 patients) were included in the meta-analysis. Exercise training improved the 400-m-walk test (MD -10.11 s, 95% CI [-14.34, -5.88]; p < 0·00001), diastolic blood pressure (-2.22 mmHg, [-3.82, -0.61]; p = 0.007), fasting blood glucose (-0.38 mmol/L, [-0.65, -0.11]; p = 0.006), C-reactive protein (-1.16 mg/L, [-2.11, -0.20]; p = 0.02), whole-body lean mass (0.70 kg, [0.39, 1.01]; p < 0.0001), appendicular lean mass (0.59 kg, [0.43, 0.76]; p < 0.00001), whole-body fat mass (-0.67 kg, [-1.08, -0.27]; p = 0.001), whole-body fat percentage (-0.79%, [-1.16, -0.42]; p < 0.0001), and trunk fat mass (-0.49 kg, [-0.87, -0.12]; p = 0.01), compared to usual care. No significant effects on systolic blood pressure or blood lipid metabolism were detected. CONCLUSIONS: In a small subset of evaluated studies, exercise may favourably improve some but not all markers of cardiometabolic health. Future exercise intervention trials with cardiometabolic outcomes as primary endpoints are needed to confirm these initial findings.
BACKGROUND: Growing evidence suggests that men exposed to androgen deprivation therapy (ADT) have an increased risk of cardiovascular disease. While exercise has shown to attenuate some adverse effects of ADT, the effects on cardiometabolic health have not been systematically evaluated. OBJECTIVE: To evaluate the effect of exercise on cardiometabolic health in men with prostate cancer (PCa) receiving ADT. METHODS: A systematic literature search of MEDLINE, EMBASE, CINHAL, SCOPUS, WEB OF SCIENCE and SPORTSDICUS from database inception to April 2020 was performed. A quantitative synthesis using Cohens d effect size and a meta-analysis using random-effects models were conducted. RESULTS: Overall, fourteen randomised controlled trials (RCTs) and four non-randomised studies were included. Eleven RCTs (n = 939 patients) were included in the meta-analysis. Exercise training improved the 400-m-walk test (MD -10.11 s, 95% CI [-14.34, -5.88]; p < 0·00001), diastolic blood pressure (-2.22 mmHg, [-3.82, -0.61]; p = 0.007), fasting blood glucose (-0.38 mmol/L, [-0.65, -0.11]; p = 0.006), C-reactive protein (-1.16 mg/L, [-2.11, -0.20]; p = 0.02), whole-body lean mass (0.70 kg, [0.39, 1.01]; p < 0.0001), appendicular lean mass (0.59 kg, [0.43, 0.76]; p < 0.00001), whole-body fat mass (-0.67 kg, [-1.08, -0.27]; p = 0.001), whole-body fat percentage (-0.79%, [-1.16, -0.42]; p < 0.0001), and trunk fat mass (-0.49 kg, [-0.87, -0.12]; p = 0.01), compared to usual care. No significant effects on systolic blood pressure or blood lipid metabolism were detected. CONCLUSIONS: In a small subset of evaluated studies, exercise may favourably improve some but not all markers of cardiometabolic health. Future exercise intervention trials with cardiometabolic outcomes as primary endpoints are needed to confirm these initial findings.
Authors: Juan Morote; Antonio Gómez-Caamaño; José L Alvarez-Ossorio; Daniel Pesqueira; Angel Tabernero; Francisco Gómez Veiga; José A Lorente; Mariano Porras; Juan J Lobato; María J Ribal; Jacques Planas Journal: J Urol Date: 2014-12-23 Impact factor: 7.450
Authors: Bradley A Wall; Daniel A GALVãO; Naeem Fatehee; Dennis R Taaffe; Nigel Spry; David Joseph; Jeffrey J Hebert; Robert U Newton Journal: Med Sci Sports Exerc Date: 2017-08 Impact factor: 5.411
Authors: Glenn N Levine; Anthony V D'Amico; Peter Berger; Peter E Clark; Robert H Eckel; Nancy L Keating; Richard V Milani; Arthur I Sagalowsky; Matthew R Smith; Neil Zakai Journal: Circulation Date: 2010-02-01 Impact factor: 29.690
Authors: N A Spry; D R Taaffe; P J England; J S Judge; D A Stephens; C Peddle-McIntyre; M K Baker; R U Newton; D A Galvão Journal: Prostate Cancer Prostatic Dis Date: 2012-08-21 Impact factor: 5.554
Authors: Matthew R Smith; Hang Lee; Francis McGovern; Mary Anne Fallon; Melissa Goode; Anthony L Zietman; Joel S Finkelstein Journal: Cancer Date: 2008-05-15 Impact factor: 6.860
Authors: Akash Nanda; Ming-Hui Chen; Brian J Moran; Michelle H Braccioforte; Daniel Dosoretz; Sharon Salenius; Michael Katin; Rudi Ross; Anthony V D'Amico Journal: Eur Urol Date: 2012-09-07 Impact factor: 20.096